GENERAL THERAPIES
Total Payments
$52.5M
Transactions
19,983
Doctors
6,731
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $3,026 | 89 | 70 |
| 2019 | $52.5M | 19,894 | 6,701 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Current or prospective ownership or investment interest | $46.2M | 49 | 88.1% |
| Travel and Lodging | $2.5M | 6,651 | 4.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 337 | 2.1% |
| Consulting Fee | $913,108 | 350 | 1.7% |
| Food and Beverage | $859,074 | 12,413 | 1.6% |
| Unspecified | $855,710 | 46 | 1.6% |
| Education | $15,227 | 126 | 0.0% |
| Royalty or License | $7,021 | 6 | 0.0% |
| Grant | $6,685 | 5 | 0.0% |
Payments by Type
General
$51.6M
19,937 transactions
Research
$855,710
46 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Cardiogenic Shock Working Group Partnership Fund | Boston Scientific Corporation | $150,000 | 0 |
| IDEAL AF | Boston Scientific Corporation | $100,000 | 0 |
| JetStream application in instent restenosis of the SFA Pop | Boston Scientific Corporation | $95,225 | 0 |
| INTERRUPT AF | Boston Scientific Corporation | $85,370 | 0 |
| Cerebral Protection of Acute Embolic Burden During Transcatheter Aortic Valve Implantation in Low Risk Patients | Boston Scientific Corporation | $74,000 | 0 |
| Cost of TAVR Complications HECON | Boston Scientific Corporation | $70,870 | 0 |
| CRT in Chemotherapy induced Cardiomyopathy | Boston Scientific Corporation | $58,143 | 0 |
| Atrial Fibrillation and Coronary Heart Disease A Long Term Perspective on the Need for Triple Antithrombotic Therapy | Boston Scientific Corporation | $37,062 | 0 |
| Same Day Subcutaneous ICD And Send Home DASH | Boston Scientific Corporation | $25,224 | 0 |
| ECG Predictors of Pacemaker Induced Cardiomyopathy | Boston Scientific Corporation | $25,000 | 0 |
| Propagation Analysis for Arrhymthmogenic Conduction Elimination to Prevent Atrial Flutter and Fibrillation Panacea AF | Boston Scientific Corporation | $25,000 | 0 |
| SYNIVUS DAPT | Boston Scientific Corporation | $22,693 | 0 |
| H FIB | Boston Scientific Corporation | $21,000 | 0 |
| RESCUE VT | Boston Scientific Corporation | $20,000 | 0 |
| Outcomes with a Systematic Application of Sentinel Cerebral Embolic Protection for Balloon Expandable TAVR A Multicenter Study | Boston Scientific Corporation | $19,000 | 0 |
| MRI PLUG Dementia Trial | Boston Scientific Corporation | $15,250 | 0 |
| Predicting the Risk of Vascular Access Complications in Patients with Peripheral Arterial Disease undergoing TAVR Insights from the Duke CT TAVR Registry ISRCAR00258 | Boston Scientific Corporation | $11,873 | 0 |
Top Doctors Receiving Payments for GENERAL THERAPIES — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Urology | Nashville, TN | $35,230 | 2 |
| , MD | Interventional Cardiology | Atlanta, GA | $34,145 | 1 |
| , M.D | Urology | San Diego, CA | $32,967 | 15 |
| , MD | Cardiovascular Disease | Oklahoma City, OK | $32,726 | 49 |
| , D.O | Clinical Cardiac Electrophysiology | Chicago, IL | $31,747 | 52 |
| , MD | Internal Medicine | Atlanta, GA | $30,652 | 14 |
| , M.D | Cardiovascular Disease | New Orleans, LA | $30,288 | 9 |
| , M.D | Urology | Los Angeles, CA | $30,190 | 11 |
| , MD | Specialist | Amarillo, TX | $29,873 | 5 |
| , MD | Clinical Cardiac Electrophysiology | Jonesboro, AR | $27,471 | 54 |
| , M.D | Internal Medicine | Boston, MA | $26,815 | 8 |
| , MD | Urogynecology and Reconstructive Pelvic Surgery | Houston, TX | $25,691 | 26 |
| , MD | Cardiovascular Disease | Philadelphia, PA | $24,961 | 33 |
| , MD | Clinical Cardiac Electrophysiology | Chicago, IL | $24,479 | 33 |
| , MD | Diagnostic Radiology | Greenville, SC | $24,181 | 1 |
| , MD | Urology | Kansas City, KS | $23,927 | 15 |
| , MD | Clinical Cardiac Electrophysiology | Lutz, FL | $23,757 | 26 |
| , M.D | Cardiovascular Disease | Rochester, MN | $23,222 | 30 |
| , MD | Urology | Chapel Hill, NC | $23,183 | 23 |
| , MD | Urology | Durham, NC | $22,945 | 15 |
| , MD | Clinical Cardiac Electrophysiology | Wheeling, WV | $22,677 | 21 |
| , MD | Vascular Surgery | Chapel Hill, NC | $22,566 | 3 |
| , MD | Urology | San Antonio, TX | $22,461 | 23 |
| , MD | Cardiovascular Disease | Cleveland, OH | $22,183 | 16 |
| , M.D | Urology | Winston Salem, NC | $21,768 | 19 |
Ad
Manufacturing Companies
- Boston Scientific Corporation $52.5M
- BOSTON SCIENTIFIC CORPORATION $3,026
Product Information
- Type Device
- Total Payments $52.5M
- Total Doctors 6,731
- Transactions 19,983
About GENERAL THERAPIES
GENERAL THERAPIES is a device associated with $52.5M in payments to 6,731 healthcare providers, recorded across 19,983 transactions in the CMS Open Payments database. The primary manufacturer is Boston Scientific Corporation.
Payment data is available from 2019 to 2020. In 2020, $3,026 was paid across 89 transactions to 70 doctors.
The most common payment nature for GENERAL THERAPIES is "Current or prospective ownership or investment interest" ($46.2M, 88.1% of total).
GENERAL THERAPIES is associated with 17 research studies, including "Cardiogenic Shock Working Group Partnership Fund" ($150,000).